Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $3.6 million.

  • Entrada Therapeutics' Non Operating Income fell 3806.8% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 844.51%. This contributed to the annual value of $19.5 million for FY2024, which is 2796.69% up from last year.
  • Per Entrada Therapeutics' latest filing, its Non Operating Income stood at $3.6 million for Q3 2025, which was down 3806.8% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Non Operating Income ranged from a high of $5.8 million in Q3 2024 and a low of $403000.0 during Q2 2022
  • Over the past 4 years, Entrada Therapeutics' median Non Operating Income value was $4.1 million (recorded in 2023), while the average stood at $3.3 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 94665.01% in 2023, then tumbled by 3806.8% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Non Operating Income stood at $950000.0 in 2022, then surged by 351.79% to $4.3 million in 2023, then increased by 19.48% to $5.1 million in 2024, then tumbled by 30.36% to $3.6 million in 2025.
  • Its Non Operating Income stands at $3.6 million for Q3 2025, versus $3.9 million for Q2 2025 and $4.4 million for Q1 2025.